Objective Cross-national replication of the high rates of overweight/obesity among U.S. pediatric cancer survivors (PCS) is limited. Predictors of weight trajectories of Israeli PCS were examined from diagnosis and end of active cancer treatment to 3 years posttreatment. Methods World Health Organization-derived body mass index (z-BMI) values were calculated at each time point from medical records of 135 Israeli PCS (M diagnosis age ¼ 11.4). A three-section piecewise multilevel model including age, ethnicity, gender, treatment length, and diagnosis as predictors was used to estimate z-BMI trajectories. Results Most participants remained at a healthy weight at all time points. Differing weight trajectories emerged for PCS diagnosed with lymphoma/leukemia versus other cancer diagnoses from diagnosis to end of treatment, but similar weight change patterns were observed posttreatment. Conclusion Replication of U.S. PCS weight trajectories was not observed in Israeli PCS, suggesting the importance of exploring environmental risk factors contributing to obesity among PCS.
Introduction
Owing to advancements in medical treatment, current survival rates of pediatric cancer patients are high, with estimates ranging from 80% to nearly 90% (Mariotto et al., 2009; Robison et al., 2005; Robison & Hudson, 2014) . However, rates of overweight and obesity among pediatric cancer survivors (PCS) also are high. According to the Childhood Cancer Survivor Studies, rates of overweight/obesity among PCS treated for acute lymphoblastic leukemia (ALL), lymphomas, and some sarcomas and central nervous system disease are as high as 40% 5 years after cancer treatment, with 21.2% of survivors classified as obese (body mass index, BMI > 95th %ile) and 20% as overweight (BMI > 85th %ile; Robison et al., 2005; Robison & Hudson, 2014) . PCS are at increased risk for a range of chronic conditions owing to their disease and treatment history. Overweight/obesity in PCS increases these health risks owing to the weight-related exacerbation of disease and treatment-related late effects on cardiac function, the endocrine system, and overall bone health (Armstrong et al., 2009; Robison & Hudson, 2014) . Available evidence suggests that both treatmentrelated cardiovascular risk factors and obesity are increasing among survivors of childhood cancer (Meacham et al., 2010) , with odds ratio estimates finding that PCS are seven times more likely to die as adults from cardiac-related diseases than those in the general population (Armstrong et al., 2009) .
Children with cancer and obesity also have poorer treatment outcomes (Amankwah, Saenz, Hale, & Brown, 2016; Orgel et al., 2014) . Although observed decreases in healthy eating and exercise among young cancer patients may be normative and adaptive during treatment (Florin et al., 2007) , PCS are at particular risk of poor outcomes if these unhealthy lifestyle patterns are maintained posttreatment (Meacham et al., 2010; Zhang & Parsons, 2015) . This is concerning given accumulating evidence suggesting that healthy lifestyle practices, including regular exercise and successful weight management, may prevent future chronic illness, reduce the risk for recurrent disease, and improve quality of life among PCS (Cox et al., 2009; Meacham et al., 2010; Zhang & Parsons, 2015) .
High rates of overweight and obesity have been documented among PCS in the United States (Amankwah et al., 2016; Stern et al., 2015; Zhang, Liu, Chung, & Kelly, 2015) . In one study (Stern et al., 2013) , a structured medical record abstraction protocol was implemented. A total of 107 available PCS medical records were reviewed for BMI percentiles from diagnosis to 5 years posttreatment. Although data up to 5 years posttreatment were reviewed, the amount of data available after 2 years posttreatment was sparse. The review of charts revealed that over one-third of PCS (including children, 5-12 years old, and adolescents, 13-17 years old) were overweight or obese at diagnosis (Stern et al., 2013) . These rates persisted and increased over a 2-year period and were found to be higher at each 6-month time point than the U.S. national overweight/obesity rates for children and adolescents (Ogden et al., 2014) . For example, Stern et al. reported that at 12 months posttreatment, 50% of the children and 52.4% of the adolescents were overweight or obese, with similar rates observed at 2 years posttreatment. Younger age and a diagnosis of leukemia or lymphoma also were predictive of higher BMI percentiles among PCS. In a recent meta-analysis, found that PCS, particularly those diagnosed with leukemia, gained substantial amounts of weight from diagnosis to maintenance. Most importantly, PCS did not return to their pretreatment weight status and were more overweight or obese compared with non-PCS 5 years after treatment. Consistent with these patterns, Withycombe et al. (2015) observed that early weight gain during treatment was a key predictor of obesity among PCS at the end of the therapy. Over 40% of the PCS they followed were either overweight or obese when they ended therapy. Overall, these findings suggest that PCS in the United States are at risk of developing overweight or obesity; however, the explicit causes of weight gain have yet to be empirically identified.
Despite consistent findings of overweight and obesity among PCS in the United States, associations between cancer and weight gain have not been clearly supported cross-nationally, raising questions about the etiology of overweight/obesity among PCS. Obesity among PCS may be due to medical treatment (e.g., type or mode of treatment, intensity and length of treatment as a function of diagnosis) or to nontreatment factors, such as changes in family dynamics and lifestyle behaviors (e.g., parental overprotectiveness, familial inactivity, family eating patterns). Notably, cancer protocols are deemed standard; thus, if the overweight and obesity rates observed among U.S. PCS primarily are due to cancer treatment, similar weight trajectories should be observed among international PCS who received comparable treatment protocols. Thus, exploration of international data of PCS weight trajectories may help clarify the extent to which treatment factors (as a function of diagnosis) contribute to overweight/obesity outcomes.
The current study sought to replicate Stern and colleagues' (2013) longitudinal examination of overweight/obesity trajectories and predictors of these trajectories among Israeli PCS. Importantly, cancer treatment in Israel follows standard U.S. and European protocols. PCS diagnosed in the United States and in Israel receive comparable treatment; thus, if weight gain is primarily associated with cancer treatment, this should be reflected in the weight trajectories of Israeli PCS. Further, data suggest comparable rates of overweight and obesity in the general population in the United States and Israel. Similar to the United States, the prevalence of overweight in Israel has tripled in the past two decades with as many as 17% of Israeli children meeting overweight criteria in 2013 (Almagor et al., 2015; Keinan-Boker, Noyman, Chinich, Green, & Nitzan-Kaluski, 2005) . The U.S. rate of youth overweight is about 18% (Ogden et al., 2014) . While overweight and obesity rates typically are combined in Israeli prevalence reports, precluding reports of obesity rates specifically, evidence of increasing obesity rates is available (OECD, 2014) . Given the standardized cancer protocols and the similar base rates of overweight, Israeli PCS represent a germane population in which to preliminarily attempt to replicate U.S. PCS weight trajectories among international PCS. We hypothesized similar initial rates of overweight/obesity in Israeli PCS as observed in prior U.S. work (Stern et al., 2013) , with increasing weight trajectories over time following active treatment.
We also considered sociodemographic and basic treatment-related factors as potential correlates and predictors of weight trajectories of Israeli PCS. Specifically, age at diagnosis, treatment length, sex, ethnicity, and type of cancer were examined. Israel is a multiethnic society and national obesity rates suggest that Arabs, particularly Arab women, are at greater risk for obesity than others living in Israel (KalterLeibovici et al., 2007; Kalter-Leibovici et al., 2012; Kaluski & Berry, 2005) . Thus, we expected an effect of ethnicity such that Arab PCS would have higher rates of obesity than Israeli PCS at diagnosis. We also expected older PCS to have higher weight at diagnosis as observed in previous research (Stern et al., 2013) . Based on a recent meta-analysis suggesting that pediatric patients diagnosed with ALL gain weight during treatment and do not return to their pretreatment weight , with similar trends observed among youth with lymphomas (Razzouk et al., 2007) , we hypothesized that PCS with these diagnoses would demonstrate higher weight at diagnosis and greater increases in weight over time compared with youth with other cancer diagnoses.
Method

Procedure
Replicating Stern and colleagues' methods (2013) , medical records of all patients receiving treatment at a major medical center in Israel were reviewed. The department of Pediatric Hematology-Oncology is the only comprehensive pediatric cancer clinic in the greater Jerusalem area, serving a large heterogeneous population from diverse ethnic and psychosocial backgrounds. Chart review began in the spring of 2014 when the first author was a visiting scholar. Institutional approval was obtained to review all available medical charts of PCS who were treated in the previous 5 years. Following Stern et al.'s (2013) structured procedures for medical record abstraction, charts were reviewed by hand and information on each patient's age, height, weight, and sex was recorded to calculate age-and sex-adjusted standardized body mass index (z-BMI) estimates. For patients receiving a diagnosis after surgery/biopsy, the date of diagnosis was adjusted to match the date of treatment (i.e., surgery) to allow for calculation of age at end of treatment (n ¼ 11). Israel-specific BMI norms do not exist; thus, the Israeli Ministry of Health uses World Health Organization (WHO) norms. As such, WHO-derived sex-and age-specific z-BMI values were calculated (de Onis et al, 2007) , wherever available, for each patient at diagnosis, end of active cancer treatment, and for 6-month intervals up to 5 years (i.e., 60 months) postdiagnosis. While medical follow-ups were intended to occur at 6-month intervals, patients' followup appointments were not always precisely scheduled and/or attended. Thus, to use the maximum amount of data available in the medical records, in about 20% of the cases, proximal measurements were used when data for a predetermined time point were missing (e.g., 6 months). Chart data from the medical appointment closest to the specified time point were used (i.e., 62 months).
Measures
Anthropometric data of objectively measured height and weight were extracted from the medical records. Birthdate, sex, height, and weight were used to calculate the WHO z-BMI-for-age norms (de Onis et al., 2007) . WHO infant norms were used to calculate z-BMI for two participants (WHO Multicentre Growth Reference Study Group, 2006) . WHO z-BMI norms end at age 19, and 23 participants aged out of the z-BMI norms during the period investigated. Following previous approaches used to bridge youth and adult BMI norms (Viner & Cole, 2006) , adult BMI z-scores were calculated using young adult Israeli BMI prevalence data (Keinan-Boker et al., 2005) . Importantly, the youth z-BMI cutoffs for overweight, obesity, and thinness are based on, and linked with, the corresponding adult BMI cutoffs; thus, including adult z-BMI scores does not change the interpretation of youth z-BMI values (Cole, Bellizzi, Flegal, & Dietz, 2000; Cole, Flegal, Nicholls & Jackson, 2007; Cole & Lobstein, 2012) .
Demographic information included sex (male, female), age at diagnosis, and ethnicity (Israeli Jewish, Arab). Treatment-related information included type of diagnosis, recoded into a binary variable reflecting lymphoma or leukemia (LL) or other cancer, and treatment length measured in years.
Participants
A total of 135 youth (n ¼ 49 females; 36.3%) were identified for chart review who had received treatment for cancer at the research site in the past 5 years. This number is estimated to be about 40% of the total of patients meeting study inclusion criteria; however, because of the nature of the project, we were only able to evaluate those medical charts that were available for review. The medical center was undergoing an updating of their medical records system and some older charts were unavailable or did not obtain both height and weight of the PCS at any time point. Of the charts reviewed, the majority of youth identified as Israeli Jewish (n ¼ 91; 67.4%) and nearly one-third were Arab (n ¼ 44; 32.6%), with an average age of 11.4 years at diagnosis (SD ¼ 4.1; range 1.30-17.71 years). LL was the most common diagnostic category (n ¼ 81; 60.4%), followed by sarcoma (n ¼ 18; 13.3%) and brain tumors (n ¼ 15, 11.1%), with 20 participants (n ¼ 14.8%) reporting other cancer diagnoses. The majority of participants received chemotherapy (n ¼ 108; 80.0%), with just over a third receiving surgery (n ¼ 52; 38.5%) and just over a quarter receiving radiation (n ¼ 39; 28.9%). A majority received only a single-treatment approach (n ¼ 82; 60.7%), with just over a third receiving a combination of treatment approaches (n ¼ 52; 38.5%). The average length of treatment was 9.8 months (M ¼ 0.81 years, SD ¼ 0.77), with a range of 0-3 years of treatment. These PCS characteristics were deemed representative of the general population seen at the Israeli medical center (personal communication, chief of pediatric hematology, 2014).
Data Analysis
Owing to the archival nature of the project, although 135 unique medical records were reviewed, missing data were such that there was no time point at which data were available for all 135 PCS. Missing data were owing to missing data in the medical record at a given time point-that is, data that were not available in the medical record in either exact or proximal form-and missing data increased at each data point. To accommodate statistically for missing data, maximum likelihood (ML) estimation was used. Missing data exceeded 50% starting at 3.5 years posttreatment. Simulation studies suggest that ML estimation produces estimates with tolerable levels of bias up to approximately 40% missing data (Dong & Peng, 2013) ; thus, data up to 3 years posttreatment were included in the present analysis (41.5% missing data).
Of the 135 PCS whose records were reviewed, 23 (17%) were missing z-BMI data at diagnosis. Compared with participants with complete data at 3 years posttreatment, those missing any data were significantly more likely to be older (M ¼ 9.08, SD ¼ 3.36 vs. M ¼ 12.11 SD ¼ 4.09 years; t(133) ¼ À3.71, p < .001). This difference is likely attributed to changing standards used in record keeping at the medical center. No other significant differences emerged.
Given the repeated measure of z-BMI within an individual, an intraclass correlation was calculated to assess the extent of data nesting. Approximately 76% of the variance in z-BMI are accounted for by the grouping structure of the data (i.e., measures within person), supporting the need to analyze the data to account for nesting. Thus, multilevel modeling was used to test hypotheses. Using restricted ML estimation, a two-level, three-section, piecewise model was used to estimate individual weight trajectories over time. The first piecewise section estimated z-BMI trajectories from baseline to end of treatment (slope 1); the second section estimated trajectories from end of treatment to 1 year posttreatment (slope 2); the third section estimated trajectories from 1 year posttreatment to 3 years posttreatment (slope 3). The final model included sex, ethnicity, age at diagnosis (grand mean centered), treatment length (grand mean centered), diagnostic category, and the interactions of diagnostic category and each of the three slopes. Treatment length and having received a combination treatment (vs. single-treatment approach) were significantly correlated (r ¼ À.19, p ¼ .027), and only treatment length accounted for any proportional variance when included in the model (see "Results" section). Thus, only treatment length was included as a covariate to preserve statistical power. Level 1 predictors included the repeated measures of z-BMI. Level 2 predictors included all patient-level variables, including sex, ethnicity, diagnostic category, age (grand mean centered), and treatment length (grand mean centered). Interactions between Level 1 intercepts and slopes and Level 2 diagnostic category also were explored and probed when significant (Preacher, Curran, & Bauer, 2006) .
Results
Preliminary Analyses
Only diagnosis and z-BMI at diagnosis were significantly correlated, r ¼ .19, p ¼ .048. No demographic or treatment variables were significantly correlated with z-BMI at any time point. Contrary to hypotheses, youth were, on average, of healthy weight at diagnosis with a mean z-BMI of À0.06 (SD ¼ 1.24; interquartile range 1.51; 95% confidence interval [À0.29, 0.18]). Over 60% of youth were of healthy weight at diagnosis (n ¼ 86; 63.7%), with 10.4% meeting criteria for overweight (n ¼ 14), 3.7% meeting criteria for obesity (n ¼ 5), and 5.1% meeting criteria for thinness/severe thinness (n ¼ 7). The percentages of youth meeting criteria for overweight or obesity remained relatively stable across all time points (Table I) . 
Weight Trajectories
Final Model Estimates
The final model included age, treatment length, sex, ethnicity, and diagnostic category, in addition to the three random intercept and slope trajectory estimates, and interactions between diagnostic category and each of the three slope estimates (Table II) . Examination of the proportional reduction in variance associated with each predictor suggested that (1) treatment length accounted for a 3% reduction in the variance of weight trajectory from 1 to 3 years posttreatment; (2) diagnostic category accounted for a 5.7% reduction in the variance of weight trajectory from diagnosis to end of treatment and a 2.8% reduction in variance of the trajectory from end of treatment to 1 year posttreatment; (3) the interaction of diagnostic category and trajectory from diagnosis to end of treatment accounted for a 20.3% reduction in variance for that initial slope; and (4) the interaction of diagnosis category and trajectory from end of treatment to 1 year posttreatment accounted for a 4.6% reduction in variance for the second slope. None of the other predictors accounted for any proportional reduction in variance.
Hypotheses were partially supported. Results suggested significant variability in youths' z-BMI percentile at diagnosis (z ¼ 6.48, p < .001), rate of weight change from diagnosis to end of treatment (z ¼ 4.64, p < .001), end of treatment to 1 year posttreatment (z ¼ 4.28, p < .001), and 1-3 years posttreatment (z ¼ 4.39, p <.001). There were significant differences in z-BMI at diagnosis based on diagnostic category (Ç ¼ .61, p ¼ .01; Table II In terms of weight trajectories, PCS with LL experienced a significant increase in z-BMI from diagnosis to end of treatment (Ç ¼ .24, p ¼ .04; Figure 1 ) and end of treatment to 1 year posttreatment (Ç ¼ .14, p ¼ .002), followed by a significant decrease in z-BMI from 1 to 3 years posttreatment (Ç ¼ À.04, p ¼ .01). PCS with LL gained, on average, 0.24 z-BMI units from diagnosis to end of treatment, and 0.14 z-BMI units every 6-month period from end of treatment to 1 year posttreatment. PCS with LL lost, on average, 0.04 z-BMI units every 6-month period from 1 to 3 years posttreatment. Diagnostic category emerged as a moderator of weight trajectories from baseline to end of treatment (Ç ¼ À.71, p < .001). Probing the interaction revealed significant differences in the direction of weight change from diagnosis to end of treatment between PCS with LL and PCS with other cancers. In contrast to the weight gain observed among PCS with LL, PCS with other cancers experienced a significant decrease in z-BMI from diagnosis to end of treatment (Ç ¼ À.47, p ¼ .004). On average, PCS with other cancers decreased by 0.47 z-BMI units from diagnosis to end of treatment.
Diagnostic category did not moderate weight trajectories from end of treatment to 1 year posttreatment (Ç ¼ .12, p ¼ .15) or from 1 to 3 years posttreatment (Ç ¼ .01, p ¼ .71); however, these interactions were probed to determine whether the rate of weight change was significant among PCS with other cancers during these posttreatment periods. Results suggested that PCS with other cancer significantly gained z-BMI from end of treatment to 1 year posttreatment (Ç ¼ .26, p ¼.004) at a rate of 0.26 z-BMI units every 6-month period, but that weight remained relatively stable 1 year posttreatment (Ç ¼ À.03, p ¼ .13).
PCS with LL and those with other cancers had similar z-BMI at end of treatment (z-BMI LL ¼ À0.10 vs. 
Discussion
The aim of the present study was to replicate work with U.S. PCS with an Israeli PCS sample and document prevalence rates of overweight/obesity and explore weight trajectories during and following treatment. Given the extant literature clearly documenting high rates of overweight/obesity among PCS over time (Amankwah et al., 2016; Robison et al., 2005; Zhang & Parsons, 2015) , and similar rates of overweight in the United States and Israel (Almagor et al., 2015; Kalter-Leibovici et al., 2007; Keinan-Boker et al., 2005) , we anticipated that Israeli PCS would have similar overweight/obesity outcomes to those observed within U.S. PCS populations. Unexpectedly, Israeli PCS were predominantly of typical healthy weight at diagnosis, and although weight change was observed over time, all weight variation remained within 1 SD of the overall population mean for z-BMI, suggesting relative weight maintenance over the course of treatment and beyond active treatment.
Hypotheses related to the impact of diagnostic category on PCS weight trajectories were partially supported in that PCS with LL initially gained weight. Indeed, research findings suggest that a diagnosis of LL is a significant risk factor for weight gain (Robison & Hudson, 2014; Withycombe et al., 2015; Zhang & Parsons, 2015) , particularly earlier in the course of treatment, and that some of this gain can be attributed to steroid medications often used in their treatment . While weight gain among PCS with LL was observed, it was notable that this weight gain ultimately was relatively minimal and did not surpass 1 SD above the population average for z-BMI. Further, by 1 year posttreatment, both PCS with LL and those with other cancer diagnoses were losing the weight they had gained. These observations are in contrast to documented weight gain among U.S. PCS with Note. WHO ¼ World Health Organization; BMI ¼ body mass index. Intervals after "end of treatment" represent 6 months posttreatment intervals up to 3 years posttreatment. LL ¼ Diagnosis of lymphoma or leukemia. Other cancer ¼ Diagnosis of cancer other than lymphoma or leukemia. Intercepts at diagnosis were significantly different. Intercepts at end of treatment, 1 year posttreatment, and 3 years posttreatment were not significantly different between groups. Slopes from diagnosis to end of treatment were significantly different between groups. Slopes from end of treatment to 1 year posttreatment and 1-3 years posttreatment were not significantly different between diagnostic groups; however, rate of weight loss from 1 year to 3 years posttreatment among pediatric cancer survivors with other cancers was not significantly different from zero.
LL, which finds the rates of obesity are often doubled following the end of the treatment (e.g., Amankwah et al., 2016; . Notably, research suggests that the WHO weight status cutoff may overestimate the number of youth meeting criteria for overweight/obesity compared with the CDC cutoffs (Wang & Chen, 2012; Yasin & Filler, 2013) . Examination of the values of z-BMI at diagnosis based on CDC and WHO-based norms demonstrated a correlation of r ¼.96, p < .001. Comparison of the number of PCS classified into each weight status category suggested that the WHO cutoffs shifted nine PCS into higher weight status categories compared with the CDC cutoffs (underweight to healthy weight, n ¼ 6; healthy weight to overweight, n ¼ 3). Even with the WHO cutoffs reflecting marginally higher proportions of PCS in the overweight category (but not obese), findings still fall short of the percentage of PCS meeting overweight/obesity criteria observed by Stern and colleagues (2013) .
Taken together, these findings suggest that in this Israeli population of PCS, weight gain may be minimal and temporary. A caveat to these results is that by examining PCS up to 3 years posttreatment, we are potentially examining only posttherapy resolution of acute cancer treatment effects. It is possible that examining these PCS over a longer period of time may demonstrate different weight trajectories, with PCS regaining weight again further out from treatment in a pattern more similar to prior reports of PCS and obesity (Amankwah et al., 2016; Zhang & Parsons, 2015) . Despite this possibility, our findings still stand in contrast to recent reports suggesting that PCS with LL often gain weight during treatment and these gains are often maintained beyond treatment through adulthood, increasing their risk for chronic health conditions (Robison & Hudson, 2014; Touyz, et al., 2016; .
Notably, no sociodemographic factors were significant predictors of z-BMI at diagnosis, and this was particularly striking for ethnicity. Established obesity risk factors of low socioeconomic status (SES) and social division are common in Israel. Although Israel is categorized as a "very highly developed" country according to the United Nation's Human Development Index, it has a poverty rate of about 35.5% (OECD, 2014) . The current study drew from a diverse population in and around Jerusalem (with 25% of the sample coming from East Jerusalem, the West Bank, and an extreme Orthodox Jewish community). Jerusalem is noted for being among the poorest cities in Israel, with >25% of its population living below the poverty line (OECD, 2014) . Health status also varies significantly within Israel, and Arabs in Israel are more likely to be both poor and live in the periphery of the country; thus, we expected to find significant excess weight among Arab PCS, as compared with Israeli Jewish PCS. Actual SES was not assessed in this study, limiting the ability to draw firm conclusions about ethnicity and z-BMI in these data; however, one possibility is that the diet of Israelis living at the poverty level may differ from the diet of those living at the poverty level in the United States.
PCS in Israel receive standard treatment and are enrolled in either United States or European protocols that are in line with universally accepted treatment recommended procedures; yet, these data suggest distinct weight trajectories from those observed among PCS in the United States (Stern et al., 2013 ) and a recent Australian study (Touyz et al., 2016) . Thus, the common conclusion that weight gain over the treatment trajectory is inevitable owing to medical factors becomes more difficult to maintain. The present findings suggest that potential nontreatment causes of overweight/obesity among U.S. PCS should be considered, especially those that may be amenable to change. For example, healthy eating and exercise behaviors tend to decline with treatment (Florin et al., 2007; Stern et al., 2015; Zhang & Parsons, 2015) and it may be that targeting these lifestyle factors earlier in the treatment process may stymie weight gain among PCS. Indeed, Withycombe et al. (2015) specifically argue that health care providers should more carefully monitor weight gains earlier in treatment to identify sooner those patients most at risk for obesity. This call is also echoed by Touyz et al. (2016) who argue that increases in BMI among PCS is likely multifactorial. Clearly, more work is needed to better understand the role that individual, family, and cultural factors have in the weight trajectories of PCS, suggesting the need for more targeted dietary and behavioral interventions earlier in the treatment process.
This study had a number of strengths including a large and diverse international sample of PCS, medical record data up to 3 years posttreatment, and a rigorous statistical approach. Nevertheless, findings should be considered in the context of a number of limitations. First, it is possible that the Israeli obesity rates are not as high as suggested in the public health reports and in the media. There has been a recent emphasis on increasing public awareness of the importance of maintaining healthy weight and behaviors, which perhaps affected the current findings (Almagor et al., 2015) . Second, Israel does not have standard national growth charts; thus, WHO (de Onis et al., 2007) growth charts were used to comprehensively explore PCS weight status. Although the Israeli Ministry of Health uses these weight standards, it is possible that the WHO data do not accurately reflect z-BMI patterns among Israeli youth. We must also acknowledge that using z-BMI to evaluate weight trajectories has its limitations in the PCS population. Other methods (e.g., three-site skinfold) to obtain an adiposity index in PCS may be preferred because BMI is not sensitive to the reduced muscle and bone mass and shorter stature of many PCS due to treatment (Karlage et al., 2015) . Third, although we believe this group of 135 PCS to be representative of the Israeli PCS population in and around Jerusalem, they still were only a portion of the available medical clinic population and may in fact be different from other sections of Israel. Replicating this study in another region of Israel would be warranted. Fourth, owing to limitations of the medical charts reviewed, we also were unable to consider treatment-related factors that might be important to evaluate, such as treatment intensity. Fifth, while data regarding treatment approach were collected, the number of combinations possible among surgery, chemotherapy, radiation, and bone marrow transplant and the low sample sizes among said combinations made it impossible to more definitely examine specific treatment type as a predictor of weight trajectories. Despite this limitation, it is important to note that including single versus combination treatment as a predictor did not account for any variance in weight trajectories in the model, but treatment length did account for a small amount of variance in weight trajectories from 1 to 3 years posttreatment, further suggesting that it may not be the treatment per se that impacts weight trajectories, but other factors.
Future research should more carefully explore nontreatment factors, such as parent and PCS behaviors and attitudes, among both Israeli and U.S. populations to better understand what may be contributing to these contrasting trajectories. Importantly, attitudes and behaviors beyond eating and exercise should be considered as risk factors. Other constructs, such as parental worry about cancer recurrence or guilt about the child's illness, may be underlying mechanisms related to excess weight (e.g., Foster et al., 2012; Molzon et al., 2014) .
Given the discrepancy between the current study and the extant literature, additional research is needed, both nationally in Israel and internationally, to elucidate associations between obesity and PCS. Previously established individual risk factors did not emerge as predictors of initial z-BMI and the longterm impact of a diagnosis of LL on weight was not observed. Perhaps most important, the overall weight of Israeli PCS remained within 1 SD of the population mean from diagnosis until 3 years posttreatment, suggesting the utility of exploring other treatment factors, such as intensity, as well as familial and cultural factors that may be specific to PCS and contribute to, as well as be protective against, weight gain among PCS in the United States and other nations. Finally, the simultaneous examination of a matched control sample of non-PCS is also needed to significantly strengthen our ability to evaluate the trajectory effects of cancer on weight in PCS over time.
